• Rotigotine and Bladder Control in Parkinson’s Rats

  2026-09-14

  The reference study connects rotigotine pharmacology with lower urinary tract dysfunction in a 6-hydroxydopamine rat model, showing that administration route and timing produce different cystometric outcomes. Its findings support careful evaluation of dopaminergic therapies for bladder overactivity rather than assuming that motor benefits predict autonomic effects.

• Pexidartinib (PLX3397) Assay Guide

  2026-09-14

  A scenario-based guide to using Pexidartinib (PLX3397), SKU B5854, in cell viability, proliferation, and cytotoxicity workflows. It explains dose design, DMSO handling, assay interpretation, macrophage biology, and practical criteria for selecting a reliable research reagent.

• Tianhuang Formula, Berberine, and RAGE/POMC

  2026-09-13

  A 2026 pre-proof study identifies RAGE/POMC signaling as a central mechanism through which berberine may protect hypothalamic neurons and improve glucolipid metabolism. Its integrated computational, cellular, and mouse-model design links neuronal apoptosis and autophagy with metabolic outcomes, while leaving causal validation and relevance to neurodegenerative disease open.

• TSPAN18–STIM1 Signaling in Prostate Cancer Bone Metastasis

  2026-09-12

  Zhou et al. identified TSPAN18 as a regulator of STIM1 stability that protects STIM1 from TRIM32-mediated ubiquitination and degradation. The resulting increase in STIM1-dependent calcium entry promotes prostate cancer migration, invasion, and bone metastasis, providing a mechanistic link between protein turnover and metastatic signaling.

• Mdivi-1 Workflow for DRP1 and Apoptosis Studies

  2026-09-11

  Build a practical Mdivi-1 workflow that connects mitochondrial fission, apoptosis, and endothelial–smooth muscle cell crosstalk. The guide translates recent hypoxia pulmonary hypertension findings into controlled assays, troubleshooting decisions, and comparison-ready readouts.

• Ertugliflozin Cardiovascular Outcomes in Type 2 Diabetes

  2026-09-11

  The VERTIS CV trial evaluated long-term cardiovascular safety of ertugliflozin in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Its main contribution was demonstrating noninferiority for major adverse cardiovascular events, while the directionally favorable heart-failure and renal findings did not establish statistical superiority.

• Sulfo-NHS-SS-Biotin for Cell-Surface Workflows

  2026-09-10

  Sulfo-NHS-SS-Biotin combines water-compatible amine labeling with a cleavable disulfide linker, making it useful for cell-surface proteomics, reversible affinity capture, and antibody workflows. This guide translates emerging glycoRNA–RNA-binding-protein biology into practical labeling, enrichment, validation, and troubleshooting decisions.

• Praeruptorin A in Poly(I:C)-Activated Macrophages

  2026-09-10

  The reference study shows that Praeruptorin A suppresses poly(I:C)-driven inflammatory activation in RAW264.7 macrophages by altering inflammatory gene programs and limiting NF-κB pathway activation. Its integrated RNA-sequencing and molecular validation workflow provides a useful framework for evaluating natural products in TLR3-associated inflammation while defining important limits for translation to other immunometabolic models.

• BGJ398: FGFR Workflow and Troubleshooting

  2026-09-09

  BGJ398 (NVP-BGJ398) enables selective interrogation of FGFR1/2/3 dependence in cancer models and offers a practical way to test FGFR signaling during comparative developmental studies. This guide connects dose-response design, pathway validation, explant experiments, and troubleshooting in one reproducible workflow.

• Patient-Derived Organoids for Breast Adenomyoepithelioma

  2026-09-09

  This reference study established and authenticated a patient-derived three-dimensional organoid model from a rare breast adenomyoepithelioma (AME). The organoids retained the tumor’s DNA signature and showed measurable responses to paclitaxel and doxorubicin, creating a practical platform for studying AME biology and treatment sensitivity.

• HotStart qPCR Master Mix for AKTIP Validation

  2026-09-08

  Translate computationally nominated AKTIP biomarkers into fast, reproducible qRT-PCR validation with hot-start specificity, fixed ROX normalization, and melt-curve quality control. This workflow is tailored to fibrolamellar carcinoma research, while remaining practical for inhibitor-challenged samples and cross-platform gene expression analysis.

• Standardized Whole-Blood Metabolic Immune Analysis

  2026-09-08

  Zhao and colleagues present a standardized whole-blood stimulation protocol for testing how metabolic interventions alter human immune responses. The workflow combines defined immune challenges, pathway-directed inhibitors, and cytokine quantification, providing a reproducible platform for cohort-scale immunometabolism studies.

• Proteinase K for DNA and EV Cargo Workflows

  2026-09-07

  Proteinase K combines broad protein digestion with compatibility across DNA isolation conditions, making it useful for genomic DNA cleanup, nuclease removal, and controlled protein-accessibility assays. This guide translates its biochemical strengths into practical workflows, including a cautious extension to Candida albicans extracellular-vesicle research.

• Neomycin Sulfate: From Mechanism to Translation

  2026-09-07

  Neomycin sulfate is more than an aminoglycoside antibiotic: its effects on RNA, DNA, and ion-channel function make it a valuable mechanistic probe. This article connects those molecular activities with experimental design, translational interpretation, and microbiome research while defining the limitations that matter for reproducibility.

• Recombinant Human Oncostatin M in Senescence Assays

  2026-09-05

  Recombinant Human Oncostatin M can do more than drive proliferation assays: it can help researchers test how cellular state shapes cytokine responsiveness. This article connects rh-Oncostatin M workflows with orthogonal fibroblast-senescence and mitochondrial-quality measurements while defining practical limits for interpretation.

8009 records 1/534 page Next 12345 下5页 Last page